Inventor · disambiguated record
Gerard M. Sullivan
Also filed as: SULLIVAN GERARD · SULLIVAN GERARD M
41 granted patents·55 pending applications·739 citations·filing 1995–2024
98Inventor score
Top patents by PatentIndex Score
96 records- 0198US8546399B2Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesBRUNCKO MILAN·Filed 2010·Granted Oct 1, 2013·100 cites·24 claims
- 0297US9174982B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Nov 3, 2015·38 cites·7 claims
- 0397US8586754B2BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesBRUNCKO MILAN·Filed 2010·Granted Nov 19, 2013·59 cites·8 claims
- 0497US8563735B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesBRUNCKO MILAN·Filed 2009·Granted Oct 22, 2013·72 cites·4 claims
- 0597US8557983B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesDOHERTY GEORGE A·Filed 2010·Granted Oct 15, 2013·44 cites·2 claims
- 0696US9029404B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted May 12, 2015·19 cites·1 claims
- 0795US8343967B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBOTT LAB·Filed 2012·Granted Jan 1, 2013·32 cites·2 claims
- 0894US9315488B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2015·Granted Apr 19, 2016·13 cites·2 claims
- 0994US9073855B2BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jul 7, 2015·11 cites·2 claims
- 1094US9045420B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jun 2, 2015·11 cites·1 claims
- 1194US8952157B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Feb 10, 2015·22 cites·5 claims
- 1294US8426422B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesHEXAMER LAURA A·Filed 2010·Granted Apr 23, 2013·49 cites·4 claims
- 1392US9403822B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2015·Granted Aug 2, 2016·9 cites·6 claims
- 1492US8940737B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2012·Granted Jan 27, 2015·7 cites·10 claims
- 1591US9303025B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Apr 5, 2016·11 cites·4 claims
- 1691US8338466B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesKUNZER AARON R·Filed 2010·Granted Dec 25, 2012·15 cites·6 claims
- 1790US9072748B2BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jul 7, 2015·11 cites·10 claims
- 1890US7456169B2Heterocyclic kinase inhibitorsABBOTT LAB·Filed 2006·Granted Nov 25, 2008·9 cites·2 claims
- 1989US9125913B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Sep 8, 2015·10 cites·6 claims
- 2088US8889675B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2012·Granted Nov 18, 2014·3 cites·9 claims
- 2187US9006247B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesTAO ZHI-FU·Filed 2011·Granted Apr 14, 2015·11 cites·5 claims
- 2287US2024285611A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2023·Application pending·0 cites
- 2386US9266877B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Feb 23, 2016·2 cites·2 claims
- 2486US9227963B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Jan 5, 2016·2 cites·2 claims
- 2586US2025313572A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2024·Application pending·0 cites
- 2686US2025019364A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2024·Application pending·0 cites
- 2784US8188077B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesDING HONG·Filed 2011·Granted May 29, 2012·8 cites·5 claims
- 2884US6310095B1Inhibitors of protein isoprenyl transferasesUNIV PITTSBURGH·Filed 1998·Granted Oct 30, 2001·39 cites·14 claims
- 2984US2025177374A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2024·Application pending·0 cites
- 3083US5631401AInhibitors of protein farnesyltransferase and squalene synthaseABBOTT LAB·Filed 1995·Granted May 20, 1997·35 cites·14 claims
- 3183US2024043404A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2023·Application pending·0 cites
- 3282US11897864B2Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2022·Granted Feb 13, 2024·0 cites·27 claims
- 3382US2024228509A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2023·Application pending·0 cites
- 3481US7956185B2Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinasesABBOTT LAB·Filed 2007·Granted Jun 7, 2011·5 cites·5 claims
- 3581US6221865B1Inhibitors of protein isoprenyl transferasesUNIV PITTSBURGH·Filed 1998·Granted Apr 24, 2001·30 cites·15 claims
- 3681US2025092062A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2024·Application pending·0 cites
- 3779US7323570B2Farnesyltransferase inhibitorsABBOTT LAB·Filed 2006·Granted Jan 29, 2008·2 cites·5 claims
- 3879US6204293B1Inhibitors of protein isoprenyl transferasesUNIV PITTSBURGH·Filed 1998·Granted Mar 20, 2001·26 cites·15 claims
- 3978US2023399340A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2022·Application pending·0 cites
- 4077US9877958B2Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2016·Granted Jan 30, 2018·1 cites·16 claims
- 4177US9844547B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2015·Granted Dec 19, 2017·1 cites·10 claims
- 4277US2024058450A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2022·Application pending·0 cites
- 4377US2022259226A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2022·Application pending·0 cites
- 4475US2020277291A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2019·Application pending·0 cites
- 4575US2023183261A1Macrocyclic MCL-1 Inhibitors and Methods of UseABBVIE INC·Filed 2022·Application pending·0 cites
- 4675US2022315555A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2021·Application pending·0 cites
- 4775US2021221789A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2020·Application pending·0 cites
- 4874US11786519B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2020·Granted Oct 17, 2023·0 cites·5 claims
- 4974US5783593AInhibitors of squalene synthetase and protein farnesyltransferaseABBOTT LAB·Filed 1996·Granted Jul 21, 1998·19 cites·26 claims
- 5074US2024199745A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 96 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →